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ABSTRACT
In total, 129 Plasmodium vivax isolates from
different geographical areas in India were ana-
lysed for point mutations in the P. vivax di-
hydrofolate reductase gene that were associated
with pyrimethamine resistance. A gradual
increase in the frequency of mutant genotypes
was observed from north to south (p <0.0001).
In the northern region (Delhi, Panna and
Nadiad), the wild-type genotype was most
prevalent, while the mutant genotype predom-
inated in the coastal regions of southern India
(Navi Mumbai, Goa and Chennai). Isolates from
the Car-Nicobar islands showed only mutant
genotypes. The differential geographical pattern
of mutations may be associated with the trans-
mission pattern.
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The worldwide spread of chloroquine-resistant
strains of Plasmodium falciparum has led to the use
of sulphadoxine–pyrimethamine as the ﬁrst-line
anti-malarial agent in south-east Asian countries.
Sulphadoxine and pyrimethamine sequentially
inhibit the dihydropteroate synthase (Dhps) and
dihydrofolate reductase (Dhfr) enzymes, respect-
ively, in the folate biosynthesis pathway to give a
synergic anti-malarial effect [1]. However, P. fal-
ciparum has overcome the effect of sulphadoxine–
pyrimethamine by evolving point mutations in
the genes encoding the Dhps and Dhfr enzymes
that reduce their drug-binding afﬁnity [2,3]. In
India, chloroquine remains the ﬁrst-line anti-
malarial agent for treatment of both P. falciparum
and Plasmodium vivax. Chloroquine resistance in
P. falciparum has been reported in India [4,5], and
areas with a chloroquine resistance level of >25%
have switched to the use of sulphadoxine–
pyrimethamine as the ﬁrst-line anti-malarial
agent. Although P. vivax is still susceptible to
chloroquine in India [6,7], the use of sulphadox-
ine–pyrimethamine to treat chloroquine-resistant
P. falciparum is creating selection pressure in the
P. vivax population. Therefore, the aim of the
present study was to obtain information concern-
ing mutations related to pyrimethamine resist-
ance in the P. vivax dhfr gene of Indian ﬁeld
isolates.
A previous study [8] identiﬁed six new muta-
tions in the P. vivax dhfr gene by sequencing, but
nonewas located in the active sites [9]. Therefore, in
order to screen ﬁeld isolates for P. vivax dhfr
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mutations, the present study used the simple
method of PCR–restriction fragment length poly-
morphism analysis. Blood samples were collected
by conducting spot surveys in different geograph-
ical regions of India, including coastal and main-
land areas (Fig. 1). Blood from P. vivax-positive
patients (diagnosed microscopically) was spotted
on autoclaved 3-mmﬁlter paper (Whatman,Mum-
bai, India), dried and stored at 4C. The study was
approved by the Ethics Committee of the National
Institute of Malaria Research (Delhi, India) and all
bloodspots were collected with the consent of the
patients. Genomic DNAwas extracted from blood-
spots using a QIAamp mini DNA kit (Qiagen,
Hilden, Germany), and this was followed by PCR
using the primers and protocols described by
Imwong et al. [10]. Sequencing of the amplicons
from 11 samples yielded results identical to the
restriction fragment length polymorphism analy-
sis, and no new mutations were detected.
In total, 129 P. vivax isolates from Delhi
(n = 29), Panna, Madhya Pradesh (6), Nadiad,
Gujarat (19), Navi Mumbai, Maharastra (11), Goa
(27), Chennai, Tamil Nadu (30) and the Car
Nicobar, Andaman and Nicobar islands (7) were
analysed for mutations at codons 33, 57, 58, 61,
117 and 173 of the P. vivax dhfr gene. Mutations
were observed only at codons 57, 58, 61 and 117
(Table 1). The data revealed a gradual increase in
the frequency of mutant genotypes from north to
south, with predominance of the wild-type geno-
type in northern regions (Delhi, Panna and
Nadiad), and mutant genotypes in southern
regions (Navi Mumbai, Goa and Chennai). A
statistically signiﬁcant difference was observed
between the datasets from the northern and
southern regions (chi-square 81.0, df 1,
p <0.0001; OR 80.5, 95% Cl 24.8–261.4). In Delhi,
26 of 29 isolates had the wild-type allele, with two
single mutations at codons 58R and 117N, and
one double mutation at 58R ⁄ 117N. In Panna, all
six isolates were wild-type. In Nadiad, 14 of 19
isolates were wild-type and ﬁve were double
mutants (58R ⁄ 117N). In Navi-Mumbai, seven of
11 isolates were double mutants (58R ⁄ 117N), two
were wild-type and two had single mutations at
codon 117N. In Goa, 26 of 30 isolates were double
mutants (58R ⁄ 117N), two were single mutants
(117N), one was a quadruple mutant
(57L ⁄ 58R ⁄ 61M ⁄ 117T), and one was wild-type. In
Chennai, 24 of 27 isolates were double mutants
(58R ⁄ 117N), one was a single mutant (codon
117N) and two were wild-type. Of the seven Car
Nicobar isolates, four showed quadruple muta-
tions (57L ⁄ 58R ⁄ 61M ⁄ 117T), one was a triple
mutant (57L ⁄ 58R ⁄ 117N), and two were double
mutants (58R ⁄ 117N). In total, six different haplo-
types, FSTS (n=51), FRTS (2), FSTN (5), FRTN (65),
LRTN (1) and LRMT (5), were observed among
the study isolates (Fig. 2).
P. vivax is the predominant malarial species on
the plains of northern India. Transmission occurs
from March to November, with an interruption in
the hot summer month of June; only during the
late post-monsoon months (September–Novem-
ber) does the number of cases of P. falciparum
malaria start to rise [11,12]. Thus, in Delhi, Panna
and Nadiad, co-infections with P. vivax and
Table 1. Mutations occurring in the Plasmodium vivax
dihydrofolate reductase gene of Indian isolates
Area
Period of
sample
collection
No. of
samples
tested
No. of isolates
Substitutions at P. vivax
dhfr codons
Wild-type Mutant F57L S58R T61M S117N/T
Delhi 2003–04 29 26 3 0 2 0 2
Panna 2003 6 6 0 0 0 0 0
Nadiad 2005 19 14 5 0 5 0 5
Navi Mumbai 2004 11 2 9 0 7 0 9
Goa 2003 30 1 29 1 27 1 28 ⁄ 1a
Chennai 2003 27 2 25 0 25 0 24
Car Nicobar 2003 7 0 7 5 7 4 3 ⁄ 4a
aS117T rather than S117N (61M and 117T based on sequencing data).
1: Delhi
2: Panna
3: Nadiad
4: NaviMumbai
5: Goa
6: Chennai
7: Car Nicobar1
3
4
5
6
7
2
Fig. 1. Location of the study sites in India.
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P. falciparum occur for a transient period only.
However, in coastal regions (Navi Mumbai, Goa
and Chennai) and island regions (Car Nicobar),
perennial co-transmission with P. falciparum and
P. vivaxmay have helped in the development and
spread of mutant genotypes.
An earlier study [8], although carried out with a
limited number of isolates, also showed a pre-
dominance of double mutants in coastal areas.
The ﬁnding of predominantly wild-type P. vivax
isolates in northern India agrees with the ﬁndings
of Ahmed et al. [13], who reported a very low
number of mutations in P. falciparum isolates from
Delhi and the neighbouring state of Uttar
Pradesh, but a high rate of mutations among
P. falciparum isolates from Goa. Similarly, in Car
Nicobar, both P. falciparum [14] and P. vivax (this
study) isolates showed a predominance of quad-
ruple mutants.
During chloroquine trials in India, 100% efﬁc-
acy was observed in patients infected with P. vi-
vax isolates showing the double mutant P. vivax
dhfr genotype [7]. Tjitra et al. [15] have demon-
strated the clinical efﬁcacy of a sulphadoxine–
pyrimethamine regimen against P. vivax patients
infected with double mutant P. vivax dhfr geno-
types in Indonesia. Based on these studies, it
appears that P. vivax is still susceptible to sulpha-
doxine–pyrimethamine in India, and that, accord-
ing to the model for evolution of drug resistance
proposed by Hastings et al. [16], Indian P. vivax
isolates are still in the ﬁrst stage of the develop-
ment and spread of resistance. The observed high
prevalence of double mutants of the P. vivax dhfr
gene among Indian ﬁeld isolates in the areas of
India with perennial co-transmission of malaria
caused by P. falciparum and P. vivax suggests that
the use of sulphadoxine–pyrimethamine as pre-
sumptive treatment for undiagnosed malaria
should be avoided.
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ABSTRACT
Preceding infections and anti-ganglioside anti-
bodies were assessed among 80 Guillain–Barre´
syndrome (GBS) patients and 125 controls. Previ-
ous infections were more frequent among GBS
patients than among controls (p <0.0001), and had
a signiﬁcant association with axonal subtype
compared with acute inﬂammatory demyelinat-
ing polyneuropathy (AIDP) (29 ⁄ 46 vs. 10 ⁄ 34
patients; p <0.05). Campylobacter jejuni (26%) was
the most common preceding infection among GBS
patients, followed by Mycoplasma pneumoniae
(15%). Anti-ganglioside antibodies were detected
more frequently among GBS patients than
among controls (65 ⁄ 80 vs. 13 ⁄ 125; p <0.001), and
a higher proportion of axonal cases had these
antibodies than did AIDP patients (43 ⁄ 46 vs.
22 ⁄ 34; p <0.01).
Keywords Anti-ganglioside antibodies, axonal sub-
type, Campylobacter jejuni, Guillain–Barre´ syndrome,
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Guillain–Barre´ syndrome (GBS) is a common
cause of acute ﬂaccid paralysis, with an annual
incidence of 1–2 cases ⁄ 100 000 population [1]. The
pathological spectrum of GBS includes acute
inﬂammatory demyelinating polyneuropathy
(AIDP), acute motor axonal neuropathy (AMAN)
and acute motor sensory axonal neuropathy
(AMSAN). One-half to two-thirds of GBS patients
usually report antecedent infections, and Campy-
lobacter jejuni, cytomegalovirus (CMV), Epstein-
Barr virus (EBV) and Mycoplasma pneumoniae are
recognised triggering agents of GBS [2]. Anti-
ganglioside antibodies are believed to play an
important role in the pathogenesis of GBS because
of molecular mimicry between some glycocon-
jugate epitopes of microbes and the nerve tissue
of the host [3]. The present study investigated
commonly described microbial infections and
anti-ganglioside antibodies in patients grouped
according to GBS subtype.
Eighty GBS patients admitted to the neurology
ward, 80 healthy volunteers matched for age and
gender, and without any history of apparent
infectious illness at the time of sample collection,
and 45 patients with neurological diseases other
than GBS, were included in a prospective case-
control study between February 2001 and March
2005. GBS patients were deﬁned according to
criteria described previously [4] and were further
subdivided into GBS subtypes [5]. Single stool
and serum samples were collected from all GBS
patients and controls with other neurological
diseases within 24–48 h of admission.
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